Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by Hopeforthebeston Jul 26, 2024 11:44am
109 Views
Post# 36149935

Re Re- Oct 8

Re Re- Oct 8 proph/gagnon said - We will hold you to your bashing as AEZS has said scale-up to 50L is "almost completed" after multiple trial production runs, delighted shareholders with the prospect of expectations of its first Health Canada approved product near at hand, and now scheduled a conference presentation before engineers on "scaleable production". Given the 5X scale-up is meaningful enough for a Health Canada approved product, and that they expect to double that scale-up to 10X or 100L by the end of the year and given the low market cap, the 5X and 10X scale-ups are meaningful. AEZS could run multiple 100L facilities and produce a number of high value products. 

The only reason I am bashing is because gagnon's word is not worth the paper it is printed on.  The 50L scale was touted by gagnon to be completed at the end of 2023 and as per yours/gagnon it is still not completed.The 100L scale up was promised around the end of Q2 2024 and it has not even been started. THIS IS NOT BASHING IT IS TRYING TO HOLD gagnon ACCOUNTABLE FOR WHAT HE SAY, JUST ASKED OATS ON HOW MUCH gagnon WORDS CAN BE TRUSTED.  
<< Previous
Bullboard Posts
Next >>